|
|||||
|
|
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer |
|
| Authors: | Bj?rn Naume Xi Zhao Marit Synnestvedt Elin Borgen Hege Giercksky Russnes Ole Christian Lingj?rde Maria Str?mberg Gro Wiedswang Gunnar Kvalheim Rolf K?resen Jahn M. Nesland Anne-Lise B?rresen-Dale Therese S?rlie |
| Affiliation: | 1. Cancer Clinic, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway;2. Department of Genetics, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway;3. Pathology Clinic, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway;4. Institute for Informatics, Faculty of Mathematics and Natural Sciences, University of Oslo, Norway;5. Department of Surgery, Ullevål University Hospital, Oslo, Norway;6. Laboratory for Cellular Therapy, Cancer Clinic, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway;7. Faculty of Medicine, University of Oslo, Norway |
| Abstract: | Expression profiles of primary breast tumors were investigated in relation to disseminated tumor cells (DTCs) in bone marrow (BM) in order to increase our understanding of the dissemination process. Tumors were classified into five pre‐defined molecular subtypes, and presence of DTC identified (at median 85 months follow‐up) a subgroup of luminal A patients with particular poor outcome (p=0.008). This was not apparent for other tumor subtypes. Gene expression profiles associated with DTC and with systemic relapse for luminal A patients were identified. This study suggests that DTC in BM differentially distinguishes clinical outcome in patients with luminal A type tumors and that DTC‐associated gene expression analysis may identify genes of potential importance in tumor dissemination. |
| Keywords: | DNA microarrays Breast cancer Micrometastases in bone marrow Molecular subtypes Clinical outcome |
| 本文献已被 ScienceDirect 等数据库收录！ | |